Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 69

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 69
---
are advised Leerink Partners that it intended to discontinue and wind up the business of Repare and did not have a standalone business plan. In addition, Leerink Partners considered the results of its efforts on behalf of Repare to solicit, at the direction of Repare, indications of interest from third parties with respect to a possible acquisition of or business combination with Repare. Leerink Partners also conducted such other financial studies and analyses and took into account such other information as it deemed appropriate. Leerink Partners assumed, without independent verification or any responsibility therefor, the accuracy and completeness of the financial, legal, regulatory, tax, accounting and other information supplied to, discussed with, or reviewed by Leerink Partners for purposes of its opinion and, with Repare’s consent, Leerink Partners 39

relied upon such information as being complete and accurate. In that regard, Leerink Partners assumed, at Repare’s direction, that the Dissolution Analysis had been reasonably prepared on
bases reflecting the best currently available estimates and judgments of the management of Repare as to the matters covered thereby and Leerink Partners relied, at Repare’s direction, on the Dissolution Analysis for purposes of its analysis
and opinion. Leerink Partners expressed no view or opinion as to the Dissolution Analysis or the assumptions on which it was based. In addition, at Repare’s direction, Leerink Partners did not make any independent evaluation or appraisal of
any of the assets or liabilities (contingent, derivative, off-balance-sheet or otherwise) of Repare, nor was Leerink Partners furnished with any such evaluation or appraisal, and Leerink Partners was not asked
to conduct, and did not conduct, a physical inspection of the properties or assets of Repare. Furthermore, at Repare’s direction Leerink Partners ascribed no value to the CVR Amount payable pursuant to the CVR Agreement. For purposes of its
opinion, Leerink Partners assumed, at the direction of the Repare Board, that the Cash Consideration would be not less than US$1.82 per Common Share.

Leerink Partners assumed, at Repare’s direction, that the final executed Agreement and CVR Agreement and the final Plan of Arrangement
would not differ in any respect material to Leerink Partners’ analysis or its opinion from the last versions of the Agreement, the CVR Agreement and the Plan of Arrangement reviewed by Leerink Partners. Leerink Partners also assumed, at
Repare’s direction, that the representations and warranties made